Trade names Ontak MedlinePlus a611024 ATC code L01XX29 (WHO) | AHFS/Drugs.com Monograph Routes of
administration Intravenous Molar mass 57,647.3 g/mol | |
Pregnancy
category US: C (Risk not ruled out) | ||
Ontak denileukin diftitox treatment of cutaneous t cell lymphoma
Denileukin diftitox (trade name Ontak) is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.
In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).
A recent study at the University of Louisville found the drug caused many stage IV cutaneous T-cell lympomas to regress or stabilize extending patient life expectancy from about eight months to more than a year; a clinically significant increase especially given the guarded prognosis of patients with advanced disseminated cutaneous T-cell lymphoma (CTCL) and the generally poor response to other available treatments.
There is some evidence tying it to vision loss and in 2006 the FDA added a black box warning to the drug's label.